The company is racing to reassure markets that it can navigate patent expirations for semaglutide – the active ingredient in its anti-obesity drugs Ozempic and Wegovy franchises, in the early 2030s
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.